ClinicalTrials.gg
TerminatedNCT01090310ENDUREUpdated Jan 14, 2016Results posted

Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis

A Phase 3 interventional study of AIN457 and Placebo in Non-infectious Uveitis, sponsored by Novartis Pharmaceuticals. Terminated at 35 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-01-14.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 44 studies in Uveitis, Intermediate with a site in United States — 2 open to participants now, 5 under way, 1 of them phase 3. Uveitis, Intermediate · United States.

Enrollment
13th of 39
86 · median 30
Started
2010
with 4 others
Phase 3
15 of 44
none open now
Registered
14th of 44
by date
Lead sponsor
5 of 44
Novartis Pharmaceuticals

Among the 44 studies in Uveitis, Intermediate with a site in United States, this one is the 13th largest by enrollment of the 39 interventional ones that give a count, is one of 5 that started in 2010, is one of 15 in phase 3, and was the 14th registered.

Uveitis, Intermediate

56 studies on the registry are indexed under Uveitis, Intermediate; 2 are open to participants now.

Browse Uveitis, Intermediate studies →

Open to participants now

2 of the 44 studies in Uveitis, Intermediate with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1 Uveitis, Intermediate study recruiting now, 1 sets no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Uveitis, Intermediate with a site in United States, or all of them as a file.
02

Study summary

This extension study will assess the safety and efficacy of AIN457 versus placebo for maintaining uveitis suppression when reducing systemic immunosuppression

03

Conditions studied

  • Non-infectious Uveitis

Keywords

  • Quiescent uveitis
  • intermediate uveitis
  • panuveitis
  • posterior uveitis
  • uveitis
  • NVS Definition: Words or phrases that best describe the protocol. Keywords help users find studies in the database.
  • Avoid acronyms, abbreviations and trade names.
  • Examples: Heart failure, aliskiren, heart attack, cardiovascular diseases
  • Psoriasis, inflammatory skin disease, scaly patches
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who have completed the entire treatment period of the 24 week core study

Exclusion criteria

Exclusion Criteria:

  • Inability or unwillingness to undergo repeated subcutaneous injections; inability to comply with study or follow-up procedures; any medical or psychiatric condition which, in the investigator's opinion wouldpreclude the participant from adhering to the protocol or completing the study per protocol.

Other protocol-defined inclusion/exclusion criteria may apply.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    AIN457 300mg every 2 weeks

    AIN457 300 mg subcutaneous (s.c.) weekly for 3 weeks followed by AIN457 300 mg s.c. every 2 weeks

    Drug: AIN457

  • Experimental
    AIN457 300 mg every 4 weeks

    AIN457 300 mg s.c. at baseline for Week 2 followed by AIN457 300 mg s.c. monthly, alternating with placebo s.c. at Weeks 1 and 4 and then monthly

    Drug: AIN457

  • Experimental
    AIN457 150 mg every 4 weeks

    AIN457 150 mg s.c. and placebo s.c. at Baseline and Week 2 followed by AIN457 150 mg s.c. monthly, alternating with placebo s.c. at Weeks 1 and 4 and then monthly

    Drug: AIN457

  • Placebo comparator
    Placebo

    Placebo s.c. every 2 weeks

    Drug: Placebo

Interventions

  • DrugSecukinumabStudies of SecukinumabSecukinumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    AIN457 150 mg powder for solution was provided in glass vials each containing 150 mg AIN457 as a lyophilized cake

  • DrugPlacebo

    Matching placebo to AIN457

06

What researchers measure

Primary outcomes

  1. The Time to the First Recurrence in Any Eye of Active Intermediate, Posterior, or Panuveitis From Baseline

    Kaplan-Meier estimates for the time to the first recurrence in any eye of active intermediate, posterior, or panuveitis from baseline defined by either: ≥ 2 step increase in vitreous haze with or without an increase in anterior chamber cell grade or decrease in best corrected visual acuity, core and extension

    Time frame: Baseline to 52 weeks

Secondary outcomes

  1. Change in Vitreous Haze Score for the Study Eye From Baseline to the Highest Post-baseline Value

    The changes in steps (0, 1, or \>= 2) from previous visit for vitreous haze, where the score is evaluated based on NEI Vitreous Haze Grading Scale (0 -4). Vitreous haze was recorded as 0-clear; to 4+ as dense opacity obscuring the optic nerve head. A 1 step increase is defined as any of the following changes: 0-1, 0.5-1, 1-2, 2-3, 3-4. A 2 step increase is defined as any of the following changes: 0-2, 0.5-2, 1-3, 2-4. A recurrent episode of active intermediate, posterior or panuveitis was considered to be resolved, if the eye returns and maintains in a quiescent state (\<1+ anterior chamber cell grade and \<1+ vitreous haze) for at least 2 weeks

    Time frame: Baseline to 52 weeks

  2. Mean Change in Best Corrected Visual Acuity From Baseline, Core and Extension

    The Best Corrected Visual Acuity (BCVA) is tested using the Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity (VA) testing protocol. VA measurements are taken in a sitting position at an initial test distance of 4 meters using ETDRS charts. The overall BCVA score is calculated using the BCVA worksheet 0-100 letter score

    Time frame: Baseline to 52 weeks

  3. Number of Participants With First Recurrence in in Any Eye of Active Intermediate, Posterior, or Panuveitis From Baseline During the Core and Extension Studies

    Evaluation of recurrence until resolution is ascertained, based on the first criteria (a \>2 step increase in vitreous haze with or without an increase in anterior chamber cell grade in either eye). A 2 step increase is defined as any of the following changes: 0-2, 0.5-2, 1-3, 2-4

    Time frame: Baseline to 52 weeks

  4. Composite Immunosuppressive Medication Score From Baseline to Week 52, Core and Extension

    IMS is a combined, single numeric score derived on the basis of the total daily dose of specific immunosuppressive agents per unit body weight, ranged on a scale from 0 to 9 for the total daily dose in milligrams per kilogram. The total IMS is the sum of the scores derived for the agents included into the score. The treatment groups will be compared using an analysis of covariance with treatment, region, and baseline IMS as covariate. The total IMS is the sum of scores derived from the agents included into the score, and ranged from 0 to 55. Treatment groups compared using analysis of covariance with treatment \& baseline IMS as covariate, where the lower IMS showed better clinical outcome.

    Time frame: Baseline to 52 weeks

07

Results

Posted Jan 14, 2016

Participant flow

Between August 2010 and March 2011, 70 patients were enrolled from 51 centers in 9 countries (United States, Germany, Switzerland, India, Spain, United Kingdom, Israel, Brazil, Italy). Recruitment was stopped due to study termination, therefore 16 out of 86 patients signed informed consent while being in core study were not enrolled into extension

Core Study
Participant flow — Core Study
MilestoneAIN457 300mg Every 2 WeeksAIN457 300 mg Every 4 WeeksAIN457 150 mg Every 4 WeeksPlacebo
Started29313134
Completed21202427
Not completed81177
Withdrew: Adverse event2211
Withdrew: Subject withdrew consent0311
Withdrew: Abnormal test procedure result0010
Withdrew: Administrative reasons5644
Withdrew: Protocol deviation1001
Extension Study
Participant flow — Extension Study
MilestoneAIN457 300mg Every 2 WeeksAIN457 300 mg Every 4 WeeksAIN457 150 mg Every 4 WeeksPlacebo
Started17161621
Completed3011
Not completed14161520
Withdrew: Aministrative problems13151418
Withdrew: Adverse event0001
Withdrew: Unsatisfactory therapeutic effect1011
Withdrew: Subject withdrew consent0100

Outcome measures

PrimaryThe Time to the First Recurrence in Any Eye of Active Intermediate, Posterior, or Panuveitis From Baseline

Kaplan-Meier estimates for the time to the first recurrence in any eye of active intermediate, posterior, or panuveitis from baseline defined by either: ≥ 2 step increase in vitreous haze with or without an increase in anterior chamber cell grade or decrease in best corrected visual acuity, core and extension

Time frame:
Baseline to 52 weeks
Reported as:
Median · Days
The Time to the First Recurrence in Any Eye of Active Intermediate, Posterior, or Panuveitis From Baseline
DaysAIN457 300mg Every 2 WeeksAIN457 300 mg Every 4 WeeksAIN457 150 mg Every 4 WeeksPlacebo
The Time to the First Recurrence in Any Eye of Active Intermediate, Posterior, or Panuveitis From BaselineNA (265.0 to NA)NA (87.0 to NA)NA (178.0 to NA)NA (228.0 to NA)
SecondaryChange in Vitreous Haze Score for the Study Eye From Baseline to the Highest Post-baseline Value

The changes in steps (0, 1, or \>= 2) from previous visit for vitreous haze, where the score is evaluated based on NEI Vitreous Haze Grading Scale (0 -4). Vitreous haze was recorded as 0-clear; to 4+ as dense opacity obscuring the optic nerve head. A 1 step increase is defined as any of the following changes: 0-1, 0.5-1, 1-2, 2-3, 3-4. A 2 step increase is defined as any of the following changes: 0-2, 0.5-2, 1-3, 2-4. A recurrent episode of active intermediate, posterior or panuveitis was considered to be resolved, if the eye returns and maintains in a quiescent state (\<1+ anterior chamber cell grade and \<1+ vitreous haze) for at least 2 weeks

Time frame:
Baseline to 52 weeks
Reported as:
Number · Number of participants
Change in Vitreous Haze Score for the Study Eye From Baseline to the Highest Post-baseline Value
Number of participantsAIN457 300mg Every 2 WeeksAIN457 300 mg Every 4 WeeksAIN457 150 mg Every 4 WeeksPlacebo
2 or more steps increase4212
1 step increase48711
No changes21212320
1 step decrease0000
2 or more steps decrease0000
SecondaryMean Change in Best Corrected Visual Acuity From Baseline, Core and Extension

The Best Corrected Visual Acuity (BCVA) is tested using the Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity (VA) testing protocol. VA measurements are taken in a sitting position at an initial test distance of 4 meters using ETDRS charts. The overall BCVA score is calculated using the BCVA worksheet 0-100 letter score

Time frame:
Baseline to 52 weeks
Reported as:
Mean · Letters
Mean Change in Best Corrected Visual Acuity From Baseline, Core and Extension
LettersAIN457 300mg Every 2 WeeksAIN457 300 mg Every 4 WeeksAIN457 150 mg Every 4 WeeksPlacebo
Mean Change in Best Corrected Visual Acuity From Baseline, Core and Extension9 ± 4.36—16 ± NA5 ± NA
SecondaryNumber of Participants With First Recurrence in in Any Eye of Active Intermediate, Posterior, or Panuveitis From Baseline During the Core and Extension Studies

Evaluation of recurrence until resolution is ascertained, based on the first criteria (a \>2 step increase in vitreous haze with or without an increase in anterior chamber cell grade in either eye). A 2 step increase is defined as any of the following changes: 0-2, 0.5-2, 1-3, 2-4

Time frame:
Baseline to 52 weeks
Reported as:
Number · Number of participants
Number of Participants With First Recurrence in in Any Eye of Active Intermediate, Posterior, or Panuveitis From Baseline During the Core and Extension Studies
Number of participantsAIN457 300mg Every 2 WeeksAIN457 300 mg Every 4 WeeksAIN457 150 mg Every 4 WeeksPlacebo
Patients with recurrence8111011
Patients with only vitreous haze criterion2342
Patients with only visual acuity criterion5869
Both criteria at the same time1000
SecondaryComposite Immunosuppressive Medication Score From Baseline to Week 52, Core and Extension

IMS is a combined, single numeric score derived on the basis of the total daily dose of specific immunosuppressive agents per unit body weight, ranged on a scale from 0 to 9 for the total daily dose in milligrams per kilogram. The total IMS is the sum of the scores derived for the agents included into the score. The treatment groups will be compared using an analysis of covariance with treatment, region, and baseline IMS as covariate. The total IMS is the sum of scores derived from the agents included into the score, and ranged from 0 to 55. Treatment groups compared using analysis of covariance with treatment \& baseline IMS as covariate, where the lower IMS showed better clinical outcome.

Time frame:
Baseline to 52 weeks
Reported as:
Mean · Units on a scale
Composite Immunosuppressive Medication Score From Baseline to Week 52, Core and Extension
Units on a scaleAIN457 300mg Every 2 WeeksAIN457 300 mg Every 4 WeeksAIN457 150 mg Every 4 WeeksPlacebo
Composite Immunosuppressive Medication Score From Baseline to Week 52, Core and Extension-5.67 ± 4.163—-1 ± NA-1 ± NA

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AIN457 300mg Every 2 Weeks—4/29 (13.8%)20/29 (69%)
AIN457 300mg Every 4 Weeks—1/31 (3.2%)19/31 (61.3%)
AIN457 150mg Every 4 Weeks—1/31 (3.2%)22/31 (71%)
Placebo Every 2 Weeks—2/33 (6.1%)22/33 (66.7%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventAIN457 300mg Every 2 WeeksAIN457 300mg Every 4 WeeksAIN457 150mg Every 4 WeeksPlacebo Every 2 Weeks
Uveitis (Study eye)Eye disorders1/290/311/310/33
Lower respiratory tract infectionInfections and infestations1/290/310/310/33
Joint dislocationInjury, poisoning and procedural complications1/290/310/310/33
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/290/310/310/33
Uveitis (Fellow eye)Eye disorders0/290/311/310/33
Mononeuropathy multiplexNervous system disorders0/291/310/310/33
SarcoidosisImmune system disorders0/290/310/311/33
Diabetes mellitusMetabolism and nutrition disorders0/290/310/311/33
Bowen's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/290/310/311/33
Seborrhoeic keratosisNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/290/310/311/33
Most frequent other events
Showing 10 of 46
Most frequent other events
EventAIN457 300mg Every 2 WeeksAIN457 300mg Every 4 WeeksAIN457 150mg Every 4 WeeksPlacebo Every 2 Weeks
NasopharyngitisInfections and infestations6/294/314/315/33
HeadacheNervous system disorders6/294/312/310/33
ArthralgiaMusculoskeletal and connective tissue disorders0/294/313/312/33
Pain in extremityMusculoskeletal and connective tissue disorders0/291/314/310/33
NauseaGastrointestinal disorders0/292/312/314/33
DizzinessNervous system disorders0/293/311/314/33
InfluenzaInfections and infestations3/293/312/310/33
CoughRespiratory, thoracic and mediastinal disorders1/290/313/312/33
Oropharyngeal painRespiratory, thoracic and mediastinal disorders2/293/311/312/33
PruritusSkin and subcutaneous tissue disorders0/293/310/310/33

Baseline characteristics

Age, Continuous
Age, Continuous(Years)AIN457 300mg Every 2 WeeksAIN457 300 mg Every 4 WeeksAIN457 150 mg Every 4 WeeksPlaceboTotal
Mean46.2 ± 14.2949.2 ± 11.1447.7 ± 13.5047.3 ± 15.4647.6 ± 13.60
Sex: Female, Male
Sex: Female, Male(Participants)AIN457 300mg Every 2 WeeksAIN457 300 mg Every 4 WeeksAIN457 150 mg Every 4 WeeksPlaceboTotal
Female1716201871
Male1215111654
08

Study locations

35 sites
  • Novartis Investigative Site
    Beverly Hills, California 90211, United States
  • Novartis Investigative Site
    Atlanta, Georgia 30322, United States
  • Novartis Investigative Site
    Louisville, Kentucky 40202, United States
  • Novartis Investigative Site
    Baltimore, Maryland 21205-2005, United States
  • Novartis Investigative Site
    Cambridge, Massachusetts 02142, United States
  • Novartis Investigative Site
    Teaneck, New Jersey 07666, United States
  • Novartis Investigative Site
    Charlotte, North Carolina 28210, United States
  • Novartis Investigative Site
    Portland, Oregon 97239, United States
  • Novartis Investigative Site
    Arlington, Texas 76012, United States
  • Novartis Investigative Site
    Houston, Texas 77025, United States
  • Novartis Investigative Site
    Sao Paulo, SP 05403-000, Brazil
  • Novartis Investigative Site
    São Paulo, SP 04023-900, Brazil
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Kiel, 24105, Germany
  • Novartis Investigative Site
    Tübingen, 72076, Germany
  • Novartis Investigative Site
    New Delhi, 110 029, India
  • Novartis Investigative Site
    Jerusalem, 9112001, Israel
  • Novartis Investigative Site
    Petach Tikva, 49100, Israel
  • Novartis Investigative Site
    Ramat Gan, 5266202, Israel
  • Novartis Investigative Site
    Tel-Aviv, 6423906, Israel
  • Novartis Investigative Site
    Barcelona, Catalunya 08035, Spain
  • Novartis Investigative Site
    Barcelona, Catalunya 08036, Spain
  • Novartis Investigative Site
    Santiago de Compostela, Galicia 15705, Spain
  • Novartis Investigative Site
    Madrid, 28040, Spain
  • Novartis Investigative Site
    Lausanne, CHE 1004, Switzerland
  • Novartis Investigative Site
    Bern, 3010, Switzerland
  • Novartis Investigative Site
    Bern, 3012, Switzerland
  • Novartis Investigative Site
    Lausanne, 1003, Switzerland
  • Novartis Investigative Site
    Luzern, 6000, Switzerland
  • Novartis Investigative Site
    St. Gallen, 9007, Switzerland
  • Novartis Investigative Site
    Zuerich, 8063, Switzerland
  • Novartis Investigative Site
    Birmingham, B18 7QU, United Kingdom
  • Novartis Investigative Site
    Liverpool, L7 8XP, United Kingdom
  • Novartis Investigative Site
    London, SE1 7EH, United Kingdom
  • Novartis Investigative Site
    York, YO31 8HE, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of Jul 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2016, 4 years 6 months after primary completion. A results delay was requested in Jul 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2010
First posted
Mar 19, 2010
Start
Aug 2010
Primary completionActual
Jul 2011
CompletionActual
Jul 2011
Results delay requested
Jul 25, 2013
Results first posted
Jan 14, 2016
Last update
Jan 14, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01090310
Responsible party
Sponsor
First posted
Mar 19, 2010
Start date
Aug 2010
Primary completion
Jul 2011
Completion
Jul 2011
Results posted
Jan 14, 2016
Last update
Jan 14, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion